Biomarkers Of Kidney Disease

Biomarkers of Kidney Disease, Second Edition, focuses on the basic and clinical research of biomarkers in common kidney diseases, detailing the characteristics of an ideal biomarker. The latest techniques for biomarker detection, including metabolomics and proteomics are covered in the book. This comprehensive book details the latest advances made in the field of biomarker research and development in kidney diseases. The book is an ideal companion for those interested in biomarker research and development, proteomics and metabolomics, kidney diseases, statistical analysis, transplantation, and preeclampsia. New chapters include biomarkers of cardiovascular disease in patients with CKD, biomarkers of Polycystic Kidney Disease, and biomarkers and the role of nanomedicine. Explores both the practical and conceptual steps performed in the discovery of biomarkers in kidney disease Presents a comprehensive account of newer biomarker discover strategies, such as metabolomics and proteomics, all illustrated by clear examples Offers clear translational presentations by the top basic and clinical researchers in each specific renal disease, including AKI, transplantation, cancer, CKD, PKD, diabetic nephropathy, preeclampsia, and glomerular disease

A biomarker is a molecule that is measured as a marker of normal biological processes, disease processes or the response to a diagnostic or therapeutic intervention. Kidney diseases like acute kidney injury, chronic kidney disease, diabetic nephropathy, glomerular disease, renal cancer and preeclampsia still have a high morbidity. Measurement of biomarkers in the blood or urine that detect patients at risk of kidney diseases or that detect kidney diseases in the earliest stage may ultimately result in preventative or earlier or more effective treatments for kidney diseases. Biomarkers of Kidney Disease reviews the basic and clinical research on biomarkers of the common kidney diseases including acute kidney injury, chronic kidney disease, renal cancer, diabetic nephropathy, glomerular disease and preeclampsia. The characteristics of an ideal biomarker of kidney diseases and statistical analysis of biomarker studies is detailed. The latest techniques for biomarker detection like metabolomics and proteomics is covered in the book. This comprehensive book details the latest advances made in the field of biomarker research and development in kidney diseases. The book is an ideal companion for those interested in biomarker research and development, proteomics and metabolomics, kidney diseases, statistical analysis, transplantation and preeclampsia. Presents a comprehensive, translational source for all aspects of renal biomarkers in one reference work Experts in renal disease biomarkers (from all areas of academic and medical research) take readers from the bench research (cellular and molecular mechanism) to new therapeutic approaches

Associated with both acute kidney injury (AKI) and cardio-renal syndromes (CRS), new biomarkers represent both a popular area of investigation and a new opportunity for advancement of therapy. This book contains the resolutions of the most recent ADQI conferences on biomarkers in AKI (Dublin) and on cardio-renal syndromes (Venice). The first part answers specific questions about new biomarkers and their use and utility in AKI: What are the most suitable candidate molecules and physiologic measures, how solid and evidence based is the discovery phase? How can we incorporate the new biomarkers in the AKI conceptual model describing the evolution from susceptibility to insult, decreased GFR and organ death? Even if we have a positive biomarker pattern and we can identify patients at risk or patients with early or even subclinical AKI, how is this information affecting our clinical behavior and practice? The second part is dedicated to the appraisal of the current knowledge about the pathophysiological mechanisms involved in different forms of CRS: it contains contributions on the state-of-the-art knowledge and practice of CRS, particularly focusing on the pathophysiology of the five subtypes. Acute and chronic mechanisms of damage are explored in depth, with particular attention to the primacy of organ involvement and the subsequent pathways of organ crosstalk.Presenting the most recent research in the field of biomarkers, AKI and CRS, this publication is an important educational tool for advanced investigators and clinical experts, but also for students and fellows.

In the past decade there has been a major sea change in the way disease is diagnosed and investigated due to the advent of high throughput technologies, such as microarrays, lab on a chip, proteomics, genomics, lipomics, metabolomics etc. These advances have enabled the discovery of new and novel markers of disease relating to autoimmune disorders, cancers, endocrine diseases, genetic disorders, sensory damage, intestinal diseases etc. In many instances these developments have gone hand in hand with the discovery of biomarkers elucidated via traditional or conventional methods, such as histopathology or clinical biochemistry. Together with microprocessor-based data analysis, advanced statistics and bioinformatics these markers have been used to identify individuals with active disease or pathology as well as those who are refractory or have distinguishing pathologies. New analytical methods that have been used to identify markers of disease and is suggested that there may be as many as 40 different platforms. Unfortunately techniques and methods have not been readily transferable to other disease states and sometimes diagnosis still relies on single analytes rather than a cohort of markers. There is thus a demand for a comprehensive and focused evidenced-based text and scientific literature that addresses these issues. Hence the formulation of Biomarkers in Disease. The series covers a wide number of areas including for example, nutrition, cancer, endocrinology, cardiology, addictions, immunology, birth defects, genetics, and so on. The chapters are written by national or international experts and specialists.

This book systematically summarizes the ideas and technologies used in urine proteome analysis. It argues that change is the core of biomarker definition since the body uses its homeostatic mechanisms to correct changes in the blood. This means that urine is probably a better source of biomarkers than blood. A roadmap to the urinary biomarker era is proposed, and researchers are reminded of the potential opportunities and risks in their study design. Kidney diseases are emphasized as they produce the most significant changes in urine. This book tries to show researchers and graduate students, who are in or entering the field, "all things considered" rather than "the current affair".

Renal Disease in Cancer Patients is a translational reference detailing the nephrological problems unique to patients with cancer in an organized and authoritative fashion. This book provides a common language for nephrologists, oncologists, hematologists, and other clinicians who treat cancer patients, to discuss the development of renal diseases in the context of cancer and options for their optimum diagnosis, management, and treatment. With the advent of better supportive care and the era of personalized medicine, patients with cancer are living longer, and oncologists and nephrologists now recognize the serious consequences of renal disease among these patients. Designed especially with this new need in mind, Renal Disease in Cancer Patients presents the various renal diseases affecting cancer patients in a single, authoritative volume. The book covers topics in radiation nephritis, obstructive nephropathy, drug nephropathy, graft-versus-host disease, and more. Covers clinical description, diagnostics, management, and treatment throughout along with genetics, animal models, and pathology in specific chapters Summarizes all renal diseases unique to cancer patients in a single reference Provides a resource for oncologists and nephrologists, as well as general internal and family medicine practitioners, and physicians in training

Advances in long-term improvement and outcomes of patients with kidney disease will require the use of novel biomarkers to identify patients at high risk for kidney disease and to diagnose kidney disease early for effective treatment. A biomarker is a substance found in the blood, body fluids or tissues that provides a measure of normal biological or pathological processes or response to pharmacological compounds or drugs. There are a wide variety of biomarkers including but not limited to mRNA, proteins and peptides, and lipid molecules. In AKI, important pathophysiological processes such as inflammation, apoptotic and necrotic cell death and, tubule regeneration may be reflected in blood or urine. An array of candidate markers along with clinical information in long-term clinical studies with appropriate analytical methodologies will likely provide prognostic information. Despite well-known limitations, currently the most widely used biomarkers for the early diagnosis of CKD and AKI are proteinuria, serum creatinine and blood urea nitrogen. Most clinicians are aware that serum creatinine and blood urea nitrogen are poor biomarkers due to inherent characteristics of these molecules and handling by the kidney. Creatinine is secreted and urea nitrogen is reabsorbed by the renal tubules. Many endogenous substances interfere in the assay for creatinine. Serum creatinine and urea appear late after acute kidney injury and the serum levels in part depend on the generation (large or small body mass). Acute kidney injury is a non steady state condition thus serum creatinine and urea nitrogen will lag behind kidney injury. For these reasons new biomarkers are imperative. With knowledge of these limitations in use of current biomarkers and the lack of progress in reducing the mortality and morbidity from kidney disease, there has been a great surge of interest in identifying novel biomarkers with a particular emphasis on the early diagnosis of kidney disease. A variety of methods have been employed including transcriptomics, proteomics, gene arrays and lipidomics. Currently, candidate biomarkers have been found in different disorders and have been tested in humans and many candidate biomarkers have yet to be identified. Most studies to date are preliminary and require validation in large multicentre studies followed by commercial assay development validation and testing. This new book outlines the rapid advances made in the field of biomarker development for kidney disease in which a variety of novel molecules have been identified and studied in humans.

This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention.